In practice the total daily dose may be divided either qid or tid. The intravenous route is preferred for severe disease [39]. For mild–moderate PCP [PaO2>9.3 kPa (>70 mmHg)], dosing is either via the oral route (TMP-SMX 1920 mg tid or 90 mg/kg/day
tid) or using the iv regimen described above [40–42]. The dose reduction from 120 mg/kg/day to 90 mg/kg/day, in severe disease, has equivalent efficacy but a lower incidence of adverse events than continuous use of higher-dose therapy [36]. Individuals with a PaO2<9.3 kPa (<70 mmHg) or SpO2<92%, should receive prednisolone 40 mg bd po, days 1–5, 40 mg od po, days 6–10, 20 mg od po, days 11–21 [43,44]; or if unable to take oral medications, methylprednisolone at 75% of this dose [45]. The benefit of corticosteroid therapy is documented only where it has been commenced within 72 h of starting specific anti-PCP therapy. A favourable treatment Birinapant clinical trial response may take 7 days or more. The decision to switch from one drug to another is driven by either treatment-limiting toxicity or lack of efficacy.
Sulphamethoxazole inhibits dihydropteroate synthase (DHPS). DHPS mutations have been associated with duration of prior TMP-SMX prophylaxis and also geographical factors, which may influence patient-to-patient transmission [46,47]. Although DHPS mutations may be found in subjects with failure of primary prophylaxis [48] it remains controversial whether these mutations influence the efficacy of treatment with TMP-SMX based regimens. Some early studies reported an association with treatment failure [47,48], while more recent work has not shown this [49–51]. One recent study suggests that the frequency of DHPS mutations may be falling this website in the HAART era in association with less long-term exposure to PCP prophylaxis [52]. Overall the outcome of PCP is more influenced by the severity of PCP than by the presence of DHPS mutations [49]. There is currently no evidence to support the routine determination of DHPS mutations; or that if
they are detected early in treatment, patients should not receive TMP-SMX (category III recommendation). In many studies salvage treatment is defined as the regimen given after a change of the primary drug regimen on the grounds of suspected treatment failure and occurring after at least 5 days of anti-PCP therapy. It is reported to Gefitinib in vitro occur in up to one-third of subjects on treatment [40–42,53,54]. Current evidence suggests that for a given level of PCP severity there is little to choose in terms of efficacy between the different second-line drugs [40–42,53]. The choice of treatment is therefore determined by patient tolerance and ability to take either oral or iv medication. For severe PCP, treatment options are clindamycin 600–900 mg qid/tid iv or 300–450 mg tid/qid po and primaquine 15–30 mg od po or pentamidine 4 mg/kg od iv for 21 days. Many clinicians favour clindamycin-based therapy in view of the toxicity profile of iv pentamidine [38,55].
Related posts:
- 7 versus 22 1) than patients who never received low-dose corticos
- After a dose of 45Gy the small bowel was excluded and an addition
- 50 Although some previous high-dose prednisone studies showed imp
- As a result, we thought that proton beam radiotherapy could deliver higher dose
- The tipping level could have a profound influence on daily life e